ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 24 for:    ESPN
Previous Study | Return to List | Next Study

Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis (PROF-ATB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02505581
Recruitment Status : Recruiting
First Posted : July 22, 2015
Last Update Posted : May 16, 2017
Sponsor:
Information provided by (Responsible Party):
Hospital Universitari Vall d'Hebron Research Institute

Brief Summary:

Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be used.

Experimental group: Patients undergoing elective colorectal surgery that involves, colonic resection.

The antibiotic prophylaxis in this group will be composed of:

An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg / 8h, 3 doses) the day before surgery.

Control group: Patients undergoing elective colorectal surgery that involves, colonic resection.

The antibiotic prophylaxis in this group will be composed of:

An intravenous antibiotic pattern of cefuroxime 1g and metronidazole 1,5gr during anesthetic induction.

In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc.

There won´t be a placebo treatment. Subject compliance will be evaluated according to the usual practice in surgical care field


Condition or disease Intervention/treatment Phase
Surgical Wound Infection Drug: Extra dosage - cefuroxime (750mg) I.V Procedure: Colorectal Surgery Drug: Cefuroxime 750mg oral Drug: Metronidazole 250mg oral Drug: Metronidazole 1,5gr Intravenous Drug: Cefuroxime 1g Intravenous Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 536 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics. A Prospective, Randomized, Controlled, Multicentric Study (PROF-ATB Trial)
Actual Study Start Date : December 2015
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : February 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oral + Parenteral prophylaxis Drug: Extra dosage - cefuroxime (750mg) I.V
In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc

Procedure: Colorectal Surgery
Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)

Drug: Cefuroxime 750mg oral
An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.

Drug: Metronidazole 250mg oral
An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.

Drug: Metronidazole 1,5gr Intravenous
An intravenous antibiotic pattern of cefuroxime 1g during anesthetic induction.

Drug: Cefuroxime 1g Intravenous
An intravenous antibiotic pattern of metronidazole 1,5gr during anesthetic induction.

Active Comparator: Only Parenteral prophylaxis Drug: Extra dosage - cefuroxime (750mg) I.V
In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc

Procedure: Colorectal Surgery
Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)

Drug: Metronidazole 1,5gr Intravenous
An intravenous antibiotic pattern of cefuroxime 1g during anesthetic induction.

Drug: Cefuroxime 1g Intravenous
An intravenous antibiotic pattern of metronidazole 1,5gr during anesthetic induction.




Primary Outcome Measures :
  1. Wound infection [ Time Frame: 30 days ]
    Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently


Secondary Outcome Measures :
  1. Hospital stay [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
    Hospital stay since colorectal surgery is done

  2. Direct Adverse Drug Reactions [ Time Frame: 24 hours since the drug is taken ]

    Allergic reactions Intolerance

    •This morbidity problems are reported independently as a YES/NO variable


  3. Occlusive problems [ Time Frame: 30 days from surgery ]

    Intestinal occlusion, Anastomotic stenosis, Prolonged ileus(>5days),.... Occlusive problems, Iatrogenic problems, Impaired healing ( Anastomotic leak rate , intestinal fistula , vesical fistula, peritonitis...) Bleeding problems, Cardiac complications, Nephro-urinary complications, Respiratory complications, Vascular Complications, Gastrointestinal complications, Neurological complications, Local complications...

    •This morbidity problems are reported independently as a YES/NO variable


  4. Iatrogenic problems [ Time Frame: 30 days after surgery ]

    Damage to structures such as ureters, bowel loops artery / iliac vein ....

    •This morbidity problems are reported independently as a YES/NO variable


  5. Impaired healing [ Time Frame: 30 days after surgery ]
    • This is a Clinical measure always supported by image tests.
    • This morbidity problems are reported independently as a YES/NO variable

  6. Bleeding problems [ Time Frame: 30 days after surgery ]

    Hemoperitoneum, abdominal hematoma,anastomotic bleeding ....

    •This morbidity problems are reported independently as a YES/NO variable


  7. Cardiac complications [ Time Frame: 30 days after surgery ]

    acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema

    • This is a Clinical measure supported by more specific tests if necessary.
    • This morbidity problems are reported independently as a YES/NO variable
    • Cardiologist report will be required for including this items

  8. Nephro-urinary complications [ Time Frame: 30 days after surgery ]

    Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ...

    • This is a Clinical measure supported by more specific tests if necessary.
    • This morbidity problems are reported independently as a YES/NO variable

  9. Respiratory complications [ Time Frame: 30 days after surgery ]

    Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ...

    • This is a Clinical measure always supported by image .
    • This morbidity problems are reported independently as a YES/NO variable

  10. Vascular Complications [ Time Frame: 30 days after surgery ]

    Deep venous thrombosis, phlebitis, thrombophlebitis, ...

    • This is a Clinical measure supported by more specific test if necessary .
    • This morbidity problems are reported independently as a YES/NO variable

  11. Gastrointestinal complications [ Time Frame: 30 days after surgery ]

    Liver failure, gastrointestinal bleeding, severe malnutrition, ...

    • This is a Clinical measure supported by blood test and further test if necessary
    • This morbidity problems are reported independently as a YES/NO variable

  12. Neurological complications [ Time Frame: 30 days after surgery ]

    Disorientation, cerebral vascular accident, ...

    • This is a Clinical measure.
    • This morbidity problems are reported independently as a YES/NO variable.
    • Neurologist report will be required beyond disorientation.

  13. Local infection [ Time Frame: 30 days after surgery ]

    Superficial, deep, body-cavity

    • This is a Clinical measure supported by image if necessary
    • This morbidity problems are reported independently as a YES/NO variable

  14. Local complications [ Time Frame: 30 days after surgery ]

    Hematoma, seroma, evisceration

    • This is a Clinical measure.
    • This morbidity problems are reported independently as a YES/NO variable



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients presenting colonic pathology
  • The surgery is not contraindicated
  • Diagnosis of colorectal neoplasia or diverticular disease with surgical indication (stenosis, chronic constipation, recurrent infections etc ..)
  • Indication of segmentary resection or total colectomy
  • Patients who agree to participate voluntarily in the study and signed an informed consent.

Exclusion Criteria:

  • Patients who refuse to participate in the study.
  • Patients undergoing mechanical colon preparation the day before surgery.
  • Patients with rectal cancer
  • Patients with intra-abdominal sepsis before surgery (abscess, diverticulitis).
  • Patients who received preoperative antibiotics for any reason in the two weeks prior to surgery.
  • Patients with inflammatory bowel disease (ulcerative colitis, Crohn's disease and indeterminate colitis)
  • Patients presenting allergy to the drugs under study.
  • Patients that will not strictly follow the assigned prophylaxis regimen
  • Patients undergoing urgent surgery (<24h)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02505581


Contacts
Contact: Eloy Espin Basany, MD PhD eespin@mac.com

Locations
Spain
Hospital de Bellvitge Recruiting
Hospitalet de Llobregat, Barcelona, Spain
Contact: Domenico Fraccalvieri, MD PhD         
Principal Investigator: Sebastiano Biondo, MD PhD         
Hospital General Universitario Vall d´Hebron Recruiting
Barcelona, Spain, 08035
Contact: Eloy Espin Basani, MD PhD       eespin@mac.com   
Principal Investigator: Eloy Espin Basani, MD PhD         
Hospital Universitari de Girona Dr. Josep Trueta Recruiting
Girona, Spain, 17007
Contact: Antonio Codina Cazador, MD PhD         
Principal Investigator: Antonio Codina Cazador, MD PhD         
Sponsors and Collaborators
Hospital Universitari Vall d'Hebron Research Institute
Investigators
Study Chair: Eloy Espin Basany, MD PhD Hospital Universitari Vall d'Hebron Research Institute

Responsible Party: Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier: NCT02505581     History of Changes
Other Study ID Numbers: 2014-002345-21
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: May 16, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Hospital Universitari Vall d'Hebron Research Institute:
Postoperative Wound Infection
Surgical Wound Infection
Colorectal Surgery Infection Prophylaxis

Additional relevant MeSH terms:
Infection
Wound Infection
Surgical Wound
Surgical Wound Infection
Wounds and Injuries
Postoperative Complications
Pathologic Processes
Anti-Bacterial Agents
Cefuroxime
Cefuroxime axetil
Antibiotics, Antitubercular
Metronidazole
Anti-Infective Agents
Antitubercular Agents
Antiprotozoal Agents
Antiparasitic Agents